Latest News
A Statement From Suzanne McGurn, President and CEO, CADTH
On behalf of the organization and our Board of Directors, I’m pleased to share the Annual ...
Target Zero is a new initiative that aims to improve the time to access for patients in Canada for new drugs that are proven to be effective.
The ...
CADTH has developed a comprehensive and accessible tool to support the validation of economic models used in health technology assessments (HTAs).
Econ ...
We are testing a new approach that brings the societal perspective to our economic evaluations of certain new drugs.
When a drug sponsor submits a drug ...
Current Consultation Status: Open Consultation Period Extended: March 28 to May 3, 2024
CADTH is updating the procedures for provisional funding ...
Qualified rare disease registry owners can submit funding proposals to enhance the infrastructure, data quality, and utility of rare disease ...